The Patent Finder

Maintenance fees coming due

Aurigene Oncology Limited

9 maintenance fees come due in the 12 months from Nov 20, 2026, the next on Dec 20, 2026. Unpaid by Jun 21, 2027, that one lapses early.
A maintenance fee does not end a patent on its due date. It falls due at 3.5, 7.5 and 11.5 years from grant, and the patent lapses only if the fee is still unpaid at the end of the six month grace period that follows.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusFee dueLapses if unpaidExpiresConfidence
US 11,680,051Crystalline Forms of 3-Substituted 1,2,4- Oxadiazole
In force
Fee due Dec 20, 2026
Lapses if unpaid Jun 21, 2027
 · High confidence
Aurigene Oncology LimitedIn forceDec 20, 2026Jun 21, 2027High confidence
US 11,691,987Bicyclic Heterocyclyl Derivatives as IRAK4 Inhibitors
In force
Fee due Jan 4, 2027
Lapses if unpaid Jul 6, 2027
 · Medium confidence
Aurigene Oncology LimitedIn forceJan 4, 2027Jul 6, 2027Medium confidence
US 10,391,082Protein Kinase Inhibitors
In force
Fee due Feb 27, 2027
Lapses if unpaid Aug 27, 2027
 · Low confidence
Aurigene Oncology LimitedIn forceFeb 27, 2027Aug 27, 2027Low confidence
US 11,865,114Method for Treating Diseases Using SMARCA2/4 Degraders
In force
Fee due Jul 9, 2027
Lapses if unpaid Jan 10, 2028
 · High confidence
Aurigene Oncology LimitedIn forceJul 9, 2027Jan 10, 2028High confidence
US 11,866,420Novel Hydrochloride Salt Forms of a Sulfonamide Structured Kinase Inhibitor
In force
Fee due Jul 9, 2027
Lapses if unpaid Jan 10, 2028
 · High confidence
Aurigene Oncology LimitedIn forceJul 9, 2027Jan 10, 2028High confidence
US 10,590,0931,2,4-Oxadiazole Derivatives as Immunomodulators
In force
Fee due Sep 17, 2027
Lapses if unpaid Mar 17, 2028
 · High confidence
Aurigene Oncology LimitedIn forceSep 17, 2027Mar 17, 2028High confidence
US 10,590,118Bicyclic Heterocyclic Derivatives as Bromodomain Inhibitors
In force
Fee due Sep 17, 2027
Lapses if unpaid Mar 17, 2028
 · High confidence
Aurigene Oncology LimitedIn forceSep 17, 2027Mar 17, 2028High confidence
US 10,640,517Bicyclic Heterocyclyl Derivatives as IRAK4 Inhibitors
In force
Fee due Nov 5, 2027
Lapses if unpaid May 5, 2028
 · High confidence
Aurigene Oncology LimitedIn forceNov 5, 2027May 5, 2028High confidence
US 11,981,685Bicyclic Heterocyclyl Derivatives as IRAK4 Inhibitors
In force
Fee due Nov 14, 2027
Lapses if unpaid May 15, 2028
 · Medium confidence
Aurigene Oncology LimitedIn forceNov 14, 2027May 15, 2028Medium confidence
9 of 9 patents shown. Soonest fee due date first, then patent number.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited